Therapeutic Sequencing Strategy in Multiple Myeloma
Date: 24th June 2021 (Thursday)
Time: 19:00 - 20:40 (GMT+8, HKT)
Meeting format: Zoom meeting
Address: Salon Room III, Hyatt Regency Hong Kong, 18 Hanoi Road, Tsim Sha Tsui, Kowloon
The survival of patients with multiple myeloma (MM) has been substantially improved in recent decades upon the introduction of new therapeutics. Particularly, the development of immunomodulatory drugs (IMiDs) has significantly improved the outcomes of patients with both newly diagnosed (NDMM) and relapsed MM (RRMM). Hence, the considerations on therapeutic sequencing throughout the course of MM, from the asymptomatic to advanced stage, have attracted the interest of both clinicians and researchers. In the webinar titled “Therapeutic Sequencing Strategy in Multiple Myeloma” organised by the Hong Kong Society of Myeloma on 24th June, 2021, Prof. María-Victoria Mateos of the University of Salamanca, Spain outlined the essentials of therapeutic sequence for patients with myeloma, with particular focus on IMiDs.
Prof. Mateos outlined the multitude of activities of IMiDs, which includes tumouricidal effects, immunomodulatory effects, and synergistic effects with other compounds. Essentially, she highlighted the efficacy of IMiDs, either as monotherapy or in combined treatment, at different stages of MM, from asymptomatic smoldering MM to refractory/relapse disease. In the event, a local case of MM management was presented by Dr. Karen HK Tang of the Queen Mary Hospital that the efficacy of lenalidomide-based therapy followed by pomalidomide-based therapy was demonstrated. The informative presentations were followed by a fruitful discussion among the keynote speakers and local clinicians.
Prof. Mateos outlined the mechanisms of action of IMiDs in combating myeloma
Dr. Tang presented the treatment protocol of her patient with RRMM
Discussion among keynote speakers and local clinicians was moderated by Prof. James Chim
